GSK, ViiV: Lupin Generic Does Not Infringe Trizivir Patent

Update on Patent Ruling on ViiV Healthcare's EPZICOM® and TRIZIVIR®

LONDON, Dec. 17, 2013 - GSK and ViiV Healthcare confirmed today that the US District Court for the District of Delaware upheld the validity of a patent covering the double combination of  lamivudine and abacavir (Epzicom®) and the triple combination of lamivudine, abacavir and zidovudine (Trizivir®).

This patent is U.S. Patent No. 6,417,191 B1, and it has an expiry date in March 2016.

Teva had previously acknowledged to the court that its generic version of Epzicom infringes the patent. There are no other challengers of this patent for Epzicom at this time.

In a separate component to the decision, the Judge ruled that the Lupin generic version of Trizivir did not infringe this combination patent. ViiV Healthcare is disappointed with this component of the court’s decision and is evaluating options for next steps in the legal process.

ViiV UK/U.S. Media enquiries:    Rebecca Hunt    +44 (0) 20 8380 6275
     Marc Meachem    +1 919 483 8756
GSK Global Media enquiries:    David Daley    +44 (0) 20 8047 5502
     Melinda Stubbee    +1 919 483 2510
GSK Analyst/Investor enquiries:    Lucy Budd    +44 (0) 20 8047 2248
     Tom Curry    + 1 215 751 5419
     Gary Davies    + 44 (0) 20 8047 5503
     James Dodwell    + 44 (0) 20 8047 2406
     Jeff McLaughlin    + 1 215 751 7002
     Ziba Shamsi    + 44 (0) 20 8047 3289
 

Posted: December 2013


View comments

Hide
(web2)